Aminocaproic acid serves as the primary therapeutic agent for managing:
Show answer Hide answer
Answer: B. Bleeding from fibrinolytic therapy
Explanation
Aminocaproic acid acts as a potent antifibrinolytic agent that competitively inhibits plasminogen activation. This targeted inhibition prevents the breakdown of fibrin clots, effectively managing excessive bleeding episodes. Consequently, it serves as the primary reversal agent for bleeding induced by therapeutic thrombolytic drugs. Fibrinolysis is the normal physiological process where blood clots are systematically degraded after vessel repair. Thrombolytic therapy intentionally activates this pathway to dissolve dangerous blood clots blocking major blood vessels. Excessive bleeding can occur when fibrinolytic activity overwhelms the normal clotting mechanisms of the body.
Emergency reversal of lytic therapy requires rapid administration of antifibrinolytic drugs to stabilize hemostasis. Surgical bleeding involving hyperfibrinolytic states also responds well to synthetic lysine analog medications. Patient safety protocols demand careful monitoring of bleeding parameters during active thrombolytic treatment courses. Acute myocardial infarction treatment involves promoting clot dissolution rather than administering antifibrinolytic agents. Heart failure management requires diuretics, vasodilators, and inotropic agents rather than clotting promoters. Multiple pulmonary emboli are treated with anticoagulants and thrombolytics to break down obstructing vascular clots.
Related questions
Q1. An acute migraine attack can typically be aborted rapidly by___________?
Show answer Hide answer
Answer: B. Ergotamine
Ergotamine acts as an agonist at vascular serotonin receptors to induce significant cranial vasoconstriction. Constricting dilated cranial blood vessels effectively interrupts the pathological mechanisms underlying acute...
Q2. All of the following medications produce xerostomia (dry mouth) except_______________?
Show answer Hide answer
Answer: D. Neostigmine
Neostigmine is an acetylcholinesterase inhibitor that increases local acetylcholine levels. Excess acetylcholine stimulates muscarinic receptors to cause excessive salivation rather than dryness. This cholinergic stimula...
Q3. Which of the following is classified as an oral hypoglycemic agent______________?
Show answer Hide answer
Answer: C. Glibeneclamide
Glibenclamide is a second generation sulfonylurea oral hypoglycemic agent that stimulates insulin secretion from pancreatic beta cells. By closing ATP sensitive potassium channels in the pancreatic beta cell membrane, it...
Q4. Which antibiotic achieves high therapeutic concentrations within dense hard tissues due to its molecular profile______________?
Show answer Hide answer
Answer: C. Clindamycin
Clindamycin possesses unique chemical properties that allow it to penetrate dense calcified matrices exceptionally well. Its excellent tissue distribution ensures high therapeutic drug levels reach infected bone structur...
Q5. Clinical indications for atropine include______________?
Show answer Hide answer
Answer: A. Organophosphate poisoning
Atropine is a competitive muscarinic receptor antagonist used as an antidote for poisoning. Organophosphates inhibit acetylcholinesterase and cause a massive accumulation of acetylcholine. Atropine blocks muscarinic rece...
Q6. Name a beta-blocker possessing intrinsic alpha-blocking activity____________?
Show answer Hide answer
Answer: D. Labetalol
Labetalol is a unique beta blocker that also possesses intrinsic alpha 1 adrenergic receptor blocking activity, promoting peripheral vasodilation. By blocking postsynaptic alpha 1 receptors on vascular smooth muscle, it...